GSK Gears Up For Three Cancer Launches In 2020

Oncology Pipeline Pivotal To Company’s Future

After selling off its oncology franchise just five years ago, GSK is poised to re-enter the fray - and is preparing its commercial teams for battle.

GSK's research location in Stevenage, UK • Source: GSK

GlaxoSmithKline PLC last week unveiled some promising figures in its Q3 last week, with robust sales of its shingles vaccine Shingrix and its HIV franchise helping to raise its 2019 profit forecast for the second time this year.

The company is also undergoing a momentous transformation, setting up its newly created consumer health joint venture with Pfizer for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

04 Jun 2025

• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

04 Jun 2025

• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.